Evidence map›Paper›PMID 26740279›Full record

ArticleScientific reports2016

Fatigue-induced Orosomucoid 1 Acts on C-C Chemokine Receptor Type 5 to Enhance Muscle Endurance.

Hong Lei, Yang Sun, Zhumin Luo, Gregory Yourek, Huan Gui, Yili Yang, Ding-Feng Su, Xia Liu

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Muscle fatigue: general understanding and treatment.Experimental & molecular medicine · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Hong LeiDepartment of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, 200433, China.
Yang SunDepartment of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, 200433, China.
Zhumin LuoDepartment of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, 200433, China.
Gregory YourekDL Biotech USA, Gaithersburg, MD, USA.
Huan GuiDepartment of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, 200433, China.
Yili YangLaboratory of Translational Medicine, Suzhou Institute of Systems Medicine, Center for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou 215123, Jiangsu, China.
Ding-Feng SuDepartment of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, 200433, China.
Xia LiuDepartment of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, 200433, China.
Second Military Medical University · CN490 BioTech (United States) · USChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding and managing fatigue is a significant challenge in clinic and society. In attempting to explore how the body responds to and regulates fatigue, we found in rodent fatigue models that orosomucoid 1 (ORM1) was significantly increased in multiple tissues, including blood and muscle. Interestingly, administration of exogenous ORM1 increased muscle glycogen and enhanced muscle endurance, whereas ORM1 deficiency resulted in a significant decrease of muscle endurance both in vivo and in vitro, which could largely be restored by exogenous ORM1. Further studies demonstrated that ORM1 can bind to C-C chemokine receptor type 5 (CCR5) on muscle cells and deletion of the receptor abolished the effect of ORM1. Thus, fatigue upregulates the level of ORM1, which in turn functions as an anti-fatigue protein to enhance muscle endurance via the CCR5 pathway. Modulation of the level of ORM1 and CCR5 signaling could be a novel strategy for the management of fatigue.

Indexed as

Muscle FatigueAnimalsCell Line, TumorHumansMice, Inbred C57BLMuscle, SkeletalOrosomucoidProtein BindingRats, Sprague-DawleyReceptors, CCR5Transcriptional ActivationOrosomucoidReceptors, CCR5

Identifiers

PMID26740279
PMCPMC4703980
OpenAlexW2225014658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.